Pengembangan RNA-LNP yang menargetkan jaringan Indonesia

• Advancements in Tissue-Specific RNA-LNP Delivery

  We always strive to improve our RNA-LNP delivery system so it can better target unhealthy tissues more successfully. This can mean producing different kind of Manufaktur Plasmid mRNA systems, but in terms of our latest progress we have been able to make RNA-LNP systems that will be applied in more ways. We can, thus, help multiple diseases of different tissues of an organ. For example there are treatments for lung diseases or even skin conditions.

• Developing RNA-LNP Delivery Systems to Target Tissue

  These RNA delivery systems have lifted the spirits of patients with those diseases that are localized to a particular tissue; Until now, there have been very limited options in treating these patients. Still, this breathtaking new technology has opened up a host of utterly novel directions for disease treatment that were once little more than science fiction.

• Providing Hope for Patients with Tissue-Specific Diseases

  In addition, potentially tissue-specific RNA-LNP platforms may be harnessed for T cell vaccine development. Similarly, we need the vaccines to be targetted at our lungs, so they will provide immune protection from other respiratory illnesses like SARS-CoV2. This result demonstrates the potential of Protokol Enkapsulasi saRNA-LNP technology not just as a therapeutic but also as prophylaxis to disease.

Why choose Yaohai Tissue-targeting RNA-LNP Development?

• Rantai Pasokan & Kemampuan Manufaktur yang Kuat

  Tissue-targeting RNA-LNP Development is a Top 10 biotech company specializing in microbiological fermentation. We have built a modern facility with strong RD capabilities and modern manufacturing facilities. Five production lines for pharmaceuticals in line with GMP standards for microbial purification and fermentation along with two automated fill and finish lines for vials and cartridges and pre-filled needles are available. The fermentation scales available are 100L, 500L, 1000L, to 2000L. Specifications for filling vials range from 1ml up to 25ml. the pre-filled syringes and cartridge filling specifications cover between 1-3ml. The workshop for production is cGMP compliant, and guarantees a stable supply of commercial products and clinical samples. Our factory produces large molecules that are shipped around the world.

• Kustomisasi, Efisiensi & Efektivitas Biaya

  Yaohai Bio-Pharma has experience in the manufacture of biologics derived from microorganisms. We offer tailored RD solutions and manufacturing while minimizing the risk. We have worked with diverse methods, such as Tissue-targeting RNA-LNP Development of vaccines (including peptides), growth factors, hormones, and Cytokines. We specialized in multiple microbial hosts, including yeast extracellular and intracellular (yield up to 15 g/L) bacteria periplasmic secretion, soluble intracellular, and inclusion bodies (yield up to 10 grams/L). We also have a BSL-2 fermentation platform to create bacterial vaccines. We specialize in improving processes, increasing product yields, as well as reducing production costs. We have an efficient technology team that guarantees timely and quality project delivery. This allows us to deliver your exclusive products quicker to market.

• Sistem Mutu & Kepatuhan Terhadap Peraturan Global

  Yaohai BioPharma, a top 10 Microbial CDMO, integrates quality and regulatory matters. We have a quality system that is fully compliant with the current GMP standards, as well as international regulations. Our team of regulatory experts has a deep understanding of world-wide regulatory frameworks. This lets us accelerate biological launches. We are able to guarantee traceable production procedures and high-quality products that conform with regulations from the US FDA, Tissue-targeting RNA-LNP Development, Australia TGA, and China NMPA. Yaohai BioPharma has successfully passed an on-site audit conducted of the European Union's Qualified Person (QP) for our GMP quality system and production site. We also have been through the initial certification audits of the ISO9001 Quality Management System and ISO14001 Environmental Management System.

• Keahlian Profesional & Pengalaman Luas

  Yaohai Bio-Pharma is a leading microbial biologics CDMO. Our main focus has been the production of Tissue-targeting RNA-LNP Development and therapeutics to treat pets, human and veterinary health. We have state-of-the-art RD platforms and manufacturing technology that cover the entire manufacturing process beginning with the development of microbial strains Cell banking, process and method development, through commercial and clinical manufacture that ensures the successful delivery of innovative solutions. Over time we've gained a vast knowledge of microbial-based bio processing. We have successfully completed more than 200 global projects, and help our clients with navigating the rules and regulations of the US FDA, EU EMA, Australia TGA, and China NMPA. We are able to react promptly to market demands and provide tailored CDMO services due to our experience and expertise.

Kategori produk terkait

• Metode Analisis DNA Plasmid
• Pembuatan VLP Bakteriofag AP205
• Pembuatan VLP Bakteriofag Q
• Pembuatan Vaksin VLP Chimeric
• Pembuatan Vaksin VLP Konjugasi
• Pembuatan Vaksin DNA
• Fermentasi E. coli untuk Produksi VLP
• Manufaktur Agonis GLP-1
• Manufaktur Analog GLP-1

Tidak menemukan apa yang Anda cari?
Hubungi konsultan kami untuk lebih banyak produk yang tersedia.